Pain, depression and inflammation: Are interconnected causative factors involved?

Modern Trends in Pharmacopsychiatry

Volumn 30, Issue , 2015, Pages 22-35

  Leonard, Brian E ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; NEUROTRANSMITTER;

BLOOD BRAIN BARRIER; CHRONIC INFLAMMATION; CHRONIC PAIN; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; HUMAN; ILLNESS BEHAVIOR; IMMUNE RESPONSE; MAJOR DEPRESSION; MENTAL DISEASE; NERVOUS SYSTEM INFLAMMATION; NEUROTRANSMISSION; PAIN; PRIORITY JOURNAL; REVIEW; STRESS; CHRONIC DISEASE; COMPLICATION; INFLAMMATION; MENTAL STRESS; PATHOPHYSIOLOGY; PSYCHOLOGY;

CHRONIC DISEASE; DEPRESSIVE DISORDER; HUMANS; INFLAMMATION; PAIN; STRESS, PSYCHOLOGICAL;

EID: 84945189648     PISSN: 16622685     EISSN: 16624505     Source Type: Book Series    
DOI: 10.1159/000435930     Document Type: Review

References (82)

1. Arnow BA, Hunkeler EM, Blasey CM, et al. Comorbid depression, chronic pain and disability in primary care. Psychosom Med 2006; 68: 262-268
2. Sansone RA, Sansone LA. Pain, pain go away: antidepressants and pain management. Psychiatry (Edgmont) 2008; 5: 16-19
3. Han C, Pae CU. Pain and depression: a neurobiological perspective of their relationship. Psychiatry Investig 2015; 12: 1-8
4. Hart BL. Biological bases of the behaviour in sick animals. Neurosci Biobehav Rev 1988; 12: 1232-1237
5. Maes M, Berk M, Goehler L, et al. Depression and sickness behaviour are Janus-faced responses to shared inflammatory pathways. BMC Med 2012; 10: 66
6. Kroeke K, Bair ML, Damush TM, et al. Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomised controlled trial. JAMA 2009; 301: 2099-2110
7. Dantzer R. Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur J Pharmacol 2004; 500: 399-411
8. Maes M, Lambrechts J, Bosmans E, et al. Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining. Psychol Med 1992; 22: 45-53
9. Capuron L, Ravand A, Dantzer R. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alpha-2b therapy. J Clin Oncol 2000; 18: 2143-2151
10. Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behaviour. Neuropsychopharmacology 2012; 37: 137-162
11. Frank MG, Barattar MV, Springer DB, et al. Microglia serve as a neuroimmune substrate for stress-induced potentiation of CNS pro-inflammatory responses. Brain Behav Immun 2007; 21: 47-59
12. Bluthe RM, Walter V, Parnet P, et al. Lipopolysaccharide induces sickness behaviour in rats mediated by vagal mediated mechanism. C R Acad Sci III 1994; 317: 499-503
13. Banks WA. Blood-brain barrier transport of cytokines: a mechanism for neuropathology. Curr Pharm Des 2005; 11: 973-984
14. Quan N, Banks WA. Brain-immune communication pathways. Brain Behav Immun 2007; 21: 727-735
15. Pariante C, Miller AH. Glucocorticoid receptors in major depression; relevance to pathophysiology and treatment. Biol Psychiatry 2001; 49: 391-404
16. Pollak Y, Yirmiya R. Cytokine induced changes in mood and behaviour; implications for 'depression due to a general medical condition', immunotherapy and antidepressant treatment. Int J Neuropsychopharmacol 2002; 5: 389-399
17. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and pathogenesis of depression. Trends Immunol 2006; 27: 24-31
18. Pace TW, Miller AH. Cytokines and glucocorticoid signaling. Relevance to major depression. Ann N Y Acad Sci 2009; 1179: 86-105
19. Asmundson GJ, Katz J. Understanding the co-occurrence of anxiety disorders and chronic pain: state-ofthe-Art. Depress Anxiety 2009; 26: 888-901
20. Butler RK, Finn DP. Stress-induced analgesia. Prog Neurobiol 2009; 88: 184-202
21. Rudy JL, Meagher MW. Fear and anxiety; divergent effects on human pain thresholds. Pain 2000; 84: 65-75
22. Crettaz B, Marziniak M, Willeke P, et al. Stress-induced allodynia; evidence of increased pain sensitivity in healthy humans and patients with chronic pain after experimentally induced social stress. PLoS One 2013; 8: e69460
23. Jennings EM, Okine BN, Roche M, Finn DP. Stressinduced hyperalgesia. Prog Neurobiol 2014; 121: 1-18
24. Olango WM, Finn DP. Neurobiology of stress induced hyperalgesia. Curr Top Behav Neurosci 2014; 20: 251-280
25. Aaron LA, Buchwald D. Chronic diffuse musculoskeletal pain, fibromyalgia and co-morbid unexplained clinical conditions. Best Pract Res Clin Rheumatol 2003; 17: 563-574
26. Grande LA, Loeser JD, Ozuma J, et al. Complex regional pain syndrome as a stress response. Pain 2004; 110: 495-498
27. McWilliams LA, Cox BJ, Enns MW. Mood and anxiety disorders associated with chronic pain; an examination in a nationally representative sample. Pain 2003; 106: 127-133
28. Fishbain DA, Goldberg M, Meagher BR, et al. Male and female chronic pain patients categorized by DSM-3 psychiatric diagnostic criteria. Pain 1986; 26: 181-197
29. Orla OR, Gelaye B, Qiu C, et al. Depression, anxiety and stress among pregnant migraineurs in a Pacific-Northwest cohort. J Affect Dis 2015; 172: 390-396
30. World Health Organisation: Headache Disorders. 2012. http://www.who.int/medcentre/factsheets/fs277/er/.
31. Frediam F, Villani V. Migraine and depression. Neurol Sci 2007; 28(suppl 2): S161-S165
32. Overeem S, Van Vliet JA, Lammers GJ, et al. The hypothalamus and episodic brain disorders. Lancet Neurol 2002; 1: 437-444
33. Christian LM, Franco A, Glaser R, Iams JD. Depressive symptoms are associated with elevated serum proinflammatory cytokines among pregnant women. Brain Behav Immun 2009; 23: 750-754
34. Mitchell AJ, Chau M, Bhatti H, et al. Prevalence of depression, anxiety and adjustment disorder in oncological, haematological and palliative care settings; a meta-Analysis of 94 interview based studies. Lancet Oncol 2011; 23: 160-174
35. Janberidze E, Hjermstad MJ, Brunelli C, et al; EURO IMPACT: The use of antidepressants in advanced cancer: results from an international multicentre study. Psychooncology 2014; 23: 1096-1102
36. Boettger MK. Antinociceptive effects of tumour necrosis factor alpha neutralisation in a rat model of antigen-induced arthritis: evidence of a neuronal target. Arthritis Rheum 2008; 58: 2368-2378
37. Marchand F. Effects of eteranercept and minaprine in a rat model of spinal cord injury. Eur J Pain 2009; 13: 673-681
38. Hess A, Axmann R, Rech J, et al. Blockade of TNF-A rapidly inhibits pain response in the central nervous system. Proc Soc Acad Sci U S A 2011; 108: 3731-3736
39. Lichstenstein GR, Bala M, Han C, et al. Infliximab improves quality of life of patients with Crohn's disease. Inflamm Bowel Dis 2002; 8: 237-243
40. Knerlich-Lukoschus F, Noack M, Van Der Ropp-Brenner B, et al. Spinal cord injuries induce changes in CB1 cannabinoid receptor and C-C chemokine expression in brain areas underlying circuitry of chronic pain conditions. J Neurotrauma 2011; 28: 619-634
41. Sulka KL. Conditional place preference paradigm: a novel approach for analgesic drug assessment against chronic pain. Pain 1994; 58: 355-366
42. Lu Y, Zhu L, Gao YJ. Pain-related aversion induces astrocytic reaction and proinflammatory cytokine expression in the anterior cingulated cortex in rats. Brain Res Bull 2011; 84: 178-182
43. Burke NN, Geoghegan E, Kerr DM, et al. Altered neuropathic pain behaviour in a rat model of depression is associated with changes in inflammatory gene expression in the amygdala. Genes Brain Behav 2013; 12: 705-713
44. Burke NN, Llorente R, Marco EM, et al. Maternal deprivation is associated with sex-dependent alterations in nociceptive behaviour and neuroinflammatory mediators in the rat following peripheral nerve injury. J Pain 2013; 14: 1173-1184
45. Ballok DA, Sakic B. Purinergic receptor antagonists moderate serology and affective behaviour in lupus prone mice: evidence of autoimmune induced pain?. Brain Behav Immun 2008; 22: 1208-1216
46. Kraepelin E. Manic-Depressive Insanity and Paranoia. Chicago, Medical Book Co, 1921
47. Huang ZL, Woode Y, Hayashi O. The role of adenosine in the regulation of sleep. Curr Top Med Chem 2011; 11: 1047-1057
48. Csolle RA, Baranyi M, Zsille G, et al. Neurochemical changes in the mouse hippocampus underlying the antidepressant effect of genetic depletion of P2X7 receptors. PLoS One 2013; 8: e66547
49. Salomone JD, Correa M. Dopamine/adenosine interactions involved in effort-related aspects of food motivation. Appetite 2009; 53: 422-425
50. Karve AV, Jagtiani SS, Chitnis KA. Evaluation of the effect of allopurinol and febuxostat in behavioural model of depression in mice. Indian J Pharmacol 2013; 45: 244-247, 422-425
51. Bauer A, Ishiwata K. Adenosine receptor ligands and PET imaging in the CNS. Handb Exp Pharmacol 2009; 617-642
52. Ortiz R, Ulrich H, Zarate CA, Machado-Vieira R. Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics. Prog Neuropsychopharm Biol Psychiatry 2015; 57: 117-131
53. Burnstock G. Physiolgy and pathophysiology of purinergic transmission. Physiol Rev 2007; 87: 659-797
54. Walker AK, Kavelaars A, Heijnen CJ, Dantzer R. Neuroinflammation and comorbidity of pain and depression. Pharmacol Rev 2014; 66: 80-101
55. Cowen PL, Perry-Billings M, Newsholme FA. Decreased plasma tryptophan levels in major depression. J Affect Dis 1989; 16: 27-31
56. Wichers MC, Koek GH, Robaeys G, et al. Indoleamine deoxygenase and interferon-Alpha induced degenerative symptoms; a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2000; 10: 538-544
57. Myint AM, Kim YK, Verkerk R, et al. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord 2007; 98: 143-151
58. Myint AM. Inflammation, neurotoxins and psychiatric disorder. Modern Trends Pharmacopsychiatri 2013; 28: 61-74
59. Steiner J, Walter M, Gos T, et al. Severe depression is associated with increased microglia quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission. J Neuroinflammation 2011; 8: 94
60. Kim JS, Schmid-Burgk W, Claus D, Kornhuber HH. Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr (1970) 1982; 232: 299-304
61. Mitani H, Shirayama Y, Yamada T, et al. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1155-1158
62. Kim H, Chen L, Lim G, et al. Brain indoleamine 2, 3-dioxygenase contributes to the comorbidity of pain and depression. J Clin Invest 2012; 122: 2940-2954
63. Li JX. Pain and depression comorbidity: a preclinical perspective. Behav Brain Res 2015; 276: 92-98
64. Mico JA, Ardidy D, Berrocoso E, et al. Antidepressants and pain. Trends Pharmacol Sci 2006; 27: 348-354
65. Esser MJ, Chase T, Allen GV, Sawynok J. Chronic administration of amitryptyline and caffeine in a rat model of neuropathic pain; multiple interactions. Eur J Pharmacol 2012; 430: 211-218
66. Burke NN, Finn DP, Roche M. Chronic administration of amitriptyline differentially alters neuropathic pain-related behaviour in the presence and absence of depressive-like phenotype. Behav Brain Res 2015; 278: 193-201
67. Chan HN, Fan J, Ng BY. Use of antidepressants in the treatment of chronic pain. Ann Acad Med Singapore 2009; 38: 974-979
68. Kim KH, Abdi S. Rediscovery of nefopam for the treatment of neuropathic. Korean J Pain 2014; 27: 103-111
69. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-Analysis. Neuropsychopharmacology 2011; 36: 2452-2459
70. Basterzi AD, Aydemir C, Kisa C, et al. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum Psychopharmacol 2005; 20: 473-476
71. O'Brien SM, Scully P, Fitzgerald P, et al. Plasma cytokine profiles of depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res 2007; 41: 326-331
72. Marks DM, Pac CU, Patkar AA. Triple reuptake inhibitors: a premise and a promise. Psychiatry Investig 2008; 5: 142-147
73. Rojewska E, Popiolek-Barczyk K, Jurga AM, et al. Involvement of pro- and antinociceptive factors in minocycline analgesia in rat neuropathic pain model. J Neuroimmunol 2014; 277: 57-66
74. Shelton RC. Does concomitant use of NSAIDs reduce the effectiveness of antidepressants?. Am J Psychiatry 2012; 169: 1012-1015
75. Burke NN, Kerr DM, Moriarty O, et al. Minocycline modulates neuropathic pain behaviour and cortical M1-M2 microglia gene expression in a rat model of depression. Brain Behav Immun 2014; 42: 147-156
76. Akhondzadeh S, Jafari S, Raisi F, et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double-blind and placebo controlled trial. Depress Anxiety 2009; 26: 607-611
77. Almeida OP, Flicker L, Yeap BB, et al. Aspirin decreases the risk of depression in old men with high plasma homocysteine. Transl Psychiatry 2012; 2: e151
78. Muller N, Schwarz MJ, Dehning S, et al. The cyclooxygenase-2-inhibitor celecoxib has therapeutic effects in depresion; results of a double-blind, randomised, placebo controlled, add-on pilot study with reboxetine. Mol Psychiatry 2006; 11: 680-684
79. Aid S, Bose HF. Targeting cyclooxygenase-1 and-2 in neuroinflammation, therapeutic implications. Biochimie 2011; 93: 46-51
80. Berk M, Dean O, Drexhage H, et al. Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Med 2013; 11: 74
81. Eyre HA, Air T, Proctor S, et al. A critical review of the efficacy of non-steroidal anti-inflammatory drugs in depression. Prog Neuropsychopharmacol Biol Psychiatry 2015; 57: 11-16
82. Maes M. Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression. Metab Brain Dis 2012; 27: 405-413